This information is disseminated under the sponsorship of the U.S. Department of Transportation in the interest of information exchange. The United States Government assumes no Liability for the contents or use thereof.

Topiramate
Description TOPAMAX ® (Topiramate) is indicated as adjunctive therapy for adults and pediatric patients ages 2-16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome. 
Therapeutic Low 1.0000
Therapeutic High 8.0000
Units ug/mL 
Specimen P 
Half Life Low 19.00
Half Life High 23.00
VOD Low 0.50
VOD High 0.80
Toxic Level 0.000
Lethal Level 0.000
Plasma to Whole Blood ratio 0.00
Warnings Adverse events most often associated with the use of TOPAMAX ® were central nervous system related. In adults, the most significant of these can be classified into two general categories: 1) psychomotor slowing, difficulty with concentration, and speech or language problems, in particular, word-finding difficulties and 2) somnolence or fatigue. Additional nonspecific CNS effects occasionally observed with topiramate as add-on therapy include dizziness or imbalance, confusion, memory problems, and exacerbation of mood disturbances (e.g., irritability and depression).